Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00641706 · ClinicalTrials.gov registry record · Phase 2
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00641706: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00641706 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00641706, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving vorinostat together with bortezomib works in treating patients with progressive, recurrent glioblastoma multiforme. Vorinostat and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vorinostat together with bortezomib may kill more tumor cells.
Interventions
- DRUG vorinostat
- PROCEDURE therapeutic conventional surgery
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2008-07 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00641706
The ClinicalTrials.gov registry entry for NCT00641706 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which vorinostat is the first listed.
NCT00641706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00641706 about?
NCT00641706 is a clinical study titled "Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme". This phase II trial is studying how well giving vorinostat together with bortezomib works in treating patients with progressive, recurrent glioblastoma multiforme. Vorinostat and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vorinostat t...
What is the current status of trial NCT00641706?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2008-07. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00641706?
The interventions under investigation include: vorinostat (DRUG), therapeutic conventional surgery (PROCEDURE), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00641706?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.